Related Experiment Video
Updated: May 29, 2026
04:03
Application of Laparoscopic Ultrasonography in Primary Choledochal Suture during Combined Two-lens Surgery
Published on: March 28, 2025
Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
C K Triantos1, N M Koukias, V N Nikolopoulou
1Department of Gastroenterology, University Hospital of Patras, Patras, Greece. chtriantos@hotmail.com
Alimentary Pharmacology & Therapeutics
|September 3, 2011
Summary
High-dose ursodeoxycholic acid (UDCA) offers no benefit for primary sclerosing cholangitis (PSC) patients. This meta-analysis found no significant improvements in mortality, symptoms, or disease progression with UDCA treatment.
Area of Science:
- Hepatology
- Gastroenterology
- Clinical Trials
Background:
- Primary sclerosing cholangitis (PSC) lacks effective medical treatments.
- Conflicting data exist on the efficacy of ursodeoxycholic acid (UDCA) in PSC.
Purpose of the Study:
- To evaluate the clinical utility of standard and high-dose UDCA in PSC through a meta-analysis.
- To assess UDCA's impact on mortality, liver transplantation, pruritus, fatigue, cholangiocarcinoma, and histological progression.
Main Methods:
- Systematic search of MEDLINE and major gastroenterology/liver meeting abstracts.
- Inclusion of eight randomized clinical trials (567 patients) comparing UDCA (standard or high-dose) against placebo or no intervention.
- Analysis of endpoints including mortality, pruritus, fatigue, cholangiocarcinoma, and histological progression.
Main Results:
- No significant differences were observed in mortality, pruritus, fatigue, cholangiocarcinoma incidence, or histological progression between UDCA and control groups.
- Subgroup analyses did not reveal any significant benefits of UDCA treatment.
- Five trials used standard UDCA doses, and three used high doses (>15 mg/kg/day).
Conclusions:
- Neither standard nor high-dose UDCA demonstrates a favorable influence on the progression of primary sclerosing cholangitis.
- Current evidence suggests UDCA is not an effective treatment for PSC.
Related Concept Videos
01:20Cholecystitis
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...